Related Experiment Video
Updated: May 10, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
A novel integrated diagnostic and therapeutic ferroptosis inhibitor based on a phenothiazine scaffold with
Jiangye Zhang1, Rui Cai2, Changxu Ning1
1State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Engineering, School of Chemical Engineering, Dalian University of Technology, Dalian 116024, China.
Abstract:
Ferroptosis is a newly discovered form of cell death that is closely related to the occurrence of various diseases, such as neurodegenerative diseases, cardiovascular and cerebrovascular ischemic damage, and organ fibrosis. Therefore, the discovery of new active compounds with ferroptosis inhibitory activity is regarded as a new strategy for the clinical treatment of these diseases. In this study, a multifunctional prodrug molecule PNX-B2 with a phenoxazine structure was designed based on the oxidative microenvironment characteristic of ferroptosis. PNX-B2 can recognize the ferroptosis-associated oxidative conditions and simultaneously release compounds with ferroptosis-inhibitory activity. Moreover, it integrates diagnostic and therapeutic functions and offers a fluorescent indication of the ferroptosis microenvironment. PNX-B2 has demonstrated excellent ferroptosis-inhibitory activity with an EC50 value of 1.7 nM. This intelligent multifunctional compound shows great potential as a novel clinical agent for ferroptosis inhibition and presents broad prospects for future development.
Insights
Researchers developed PNX-B2, a novel prodrug targeting ferroptosis, a cell death linked to diseases. This compound inhibits ferroptosis, offering diagnostic and therapeutic benefits for related conditions.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Ferroptosis is a cell death pathway implicated in various diseases, including neurodegeneration and organ damage.
- Targeting ferroptosis presents a promising therapeutic strategy for these conditions.
- Developing novel compounds with ferroptosis inhibitory activity is crucial for clinical applications.
Purpose of the Study:
- To design and synthesize a multifunctional prodrug, PNX-B2, capable of targeting the oxidative microenvironment characteristic of ferroptosis.
- To evaluate the ferroptosis-inhibitory activity and diagnostic capabilities of PNX-B2.
- To explore the potential of PNX-B2 as a novel clinical agent for ferroptosis-related diseases.
Main Methods:
- Design of a phenoxazine-based prodrug molecule (PNX-B2) responsive to ferroptosis-associated oxidative conditions.
- In vitro evaluation of PNX-B2's ability to recognize oxidative stress and release active ferroptosis-inhibitory compounds.
- Assessment of PNX-B2's diagnostic function through fluorescent indication of the ferroptosis microenvironment.
- Quantification of ferroptosis-inhibitory activity using EC50 values.
Main Results:
- PNX-B2 successfully recognized ferroptosis-associated oxidative conditions.
- The prodrug demonstrated simultaneous release of ferroptosis-inhibitory compounds.
- PNX-B2 integrated diagnostic and therapeutic functions, providing fluorescent feedback.
- PNX-B2 exhibited potent ferroptosis-inhibitory activity with an EC50 of 1.7 nM.
Conclusions:
- PNX-B2 is an intelligent, multifunctional prodrug with excellent ferroptosis-inhibitory efficacy.
- The compound's ability to target oxidative stress and its dual diagnostic/therapeutic functions highlight its potential.
- PNX-B2 shows significant promise as a novel clinical agent for treating ferroptosis-related diseases.
